Rekvina Labs Ltd.
| BSE: 526075 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE092O01028 |
| BSE 00:00 | 13 Dec | Rekvina Labs Ltd |
| NSE 05:30 | 01 Jan | Rekvina Labs Ltd |
| OPEN | 4.50 |
| PREVIOUS CLOSE | 4.50 |
| VOLUME | 21 |
| 52-Week high | 4.58 |
| 52-Week low | 3.80 |
| P/E | |
| Mkt Cap.(Rs cr) | 3 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Rekvina Labs Ltd. (REKVINALABS) - Net Profit
Net Profit
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
| Cipla | 1028.85 | -3.25 | -0.31 | 2957.93 |
| Divi's Lab. | 3698.00 | -46.40 | -1.24 | 2948.54 |
| Glaxosmi. Pharma | 1481.75 | 3.15 | 0.21 | 1690.53 |
| Glenmark Pharma. | 388.30 | -11.30 | -2.83 | 1649.45 |
| Dr Reddy's Labs | 4207.55 | -18.00 | -0.43 | 1623.20 |
| Alkem Lab | 2925.00 | -2.55 | -0.09 | 1541.25 |
| Aurobindo Pharma | 570.05 | -12.90 | -2.21 | 1454.71 |
| Gland Pharma | 2430.75 | 31.65 | 1.32 | 1212.16 |
| Alembic Pharma | 650.25 | -4.45 | -0.68 | 1175.39 |
| Torrent Pharma. | 1543.50 | -16.75 | -1.07 | 991.45 |
| Sanofi India | 6336.80 | -38.20 | -0.60 | 944.40 |
| Ipca Labs. | 906.65 | -18.35 | -1.98 | 870.94 |
| Zydus Lifesci. | 388.05 | -6.05 | -1.54 | 857.90 |
| Abbott India | 18886.45 | -125.55 | -0.66 | 798.70 |
| Laurus Labs | 583.00 | -7.25 | -1.23 | 750.09 |
| Ajanta Pharma | 1276.05 | 17.40 | 1.38 | 719.86 |
| Apollo Hospitals | 4163.00 | -107.55 | -2.52 | 665.20 |
| Pfizer | 4222.45 | 7.15 | 0.17 | 612.56 |
| Piramal Enterp. | 1974.50 | 12.35 | 0.63 | 572.28 |
| Suven Pharma | 448.85 | -3.40 | -0.75 | 558.10 |
Quick Links for Rekvina Labs:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
